Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $118.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 163.10% from the company’s current price. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.

Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Wedbush restated a “neutral” rating and set a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Finally, Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $92.43.

Ultragenyx Pharmaceutical Stock Up 4.4 %

Shares of NASDAQ:RARE opened at $44.85 on Wednesday. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The firm’s 50-day simple moving average is $44.63 and its 200-day simple moving average is $49.59. The company has a market cap of $4.14 billion, a price-to-earnings ratio of -6.93 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The company had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.23) EPS. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -6.14 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth about $103,000. KBC Group NV lifted its holdings in shares of Ultragenyx Pharmaceutical by 2,275.8% during the 4th quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock worth $2,567,000 after acquiring an additional 58,442 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 294 shares during the last quarter. Nordea Investment Management AB grew its holdings in Ultragenyx Pharmaceutical by 8.9% in the fourth quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock valued at $1,658,000 after purchasing an additional 3,246 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Ultragenyx Pharmaceutical by 740.0% during the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after purchasing an additional 76,150 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.